The increased incidence of parallel tubular structures in lymphocytes of patients with Hodgkin’s disease was investigated for a correlation with either impairment of cellular immunity (measured by DNCB-skin test and PHA-induced lymphocyte stimulation in vitro) or an increase of antibodies against cytomegalovirus or Epstein-Barr virus. No correlations were found. Statistical analysis revealed antibody titers especially in the group of patients with high percentages of lymphocytes containing the tubular inclusions. This probably reflects only the connection between these findings and the progression of the disease. The nature and function of the parallel tubular structures have to be investigated further. In Hodgkin’s disease they may have significance for the understanding of an alteration in lymphocyte function and morphology.

Keywords:
Cellular immunity, CMV antibodies, EBV antibodies, Hodgkin’s disease, Lymphocyte inclusions, Tubular structures in lymphocytes, Ultrastructure of lymphocytes
This content is only available via PDF.
© 1975 S. Karger AG, Basel
1975
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.